Overview Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Status: Completed Trial end date: 2009-02-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults. Phase: Phase 2 Details Lead Sponsor: Revance Therapeutics, Inc.